Drug Trial Radar · NCT05405725
A Phase 3 Study to Compare Biosimilar Denosumab With Prolia®
Last checked: Nov 20, 2026Latest source record: Feb 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
504
Actual
Start
Jul 4, 2022
Primary completion
Jul 18, 2024
Study completion Jul 18, 2024
Sponsor
- Lead sponsor
- Enzene Biosciences Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- Alkem Laboratories Ltd
- First posted
- Jun 6, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 55 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The Study will be conducted to Compare the Efficacy, Safety, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Enzene Denosumab (ENZ215) and Prolia® in Postmenopausal Women with Osteoporosis. The primary goal for the study is 1. To evaluate the efficacy of ENZ215 when compared to Prolia® in patients with postmenopausal osteoporosis, in terms of change in BMD at the lumbar spine from baseline to Month 12 and 2. To compare the AUEC of sCTX levels from baseline to Month 6
Conditions
- Postmenopausal Osteoporosis
Interventions
ENZ215Biological
Enrolled women with postmenopausal osteoporosis receive ENZ215 (60mg)
ProliaBiological
Enrolled women with postmenopausal osteoporosis receive Prolia
Primary outcomes
What the sponsor says the trial is designed to measure.
- To Evaluate the Efficacy of ENZ215 When Compared to Prolia in Patients With Postmenopausal Osteoporosis, in Terms of Change in Bone Mineral Density (BMD) at Lumbar Spine.Time frame: Month 12
- Area Under the Effect Curve (AUEC) of % Change From Baseline (%CfB) of Serum C-telopeptide of Type-1 Collagen (sCTX) LevelsTime frame: Month 6
Locations
48 sites in 7 countries. Site status is shown where the registry gives one.
University Hospital
Plovdiv, Bulgaria
Medical Center Teodora,
Rousse, Bulgaria
DCC XVII-Sofia EOOD
Sofia, Bulgaria
Research Center(Medical Center Synexus Sofia EOOD)
Sofia, Bulgaria
Research Center
Brno, Czechia
G-CENTRUM Olomouc
Horní Město, Czechia
Research Center
Pardubice, Czechia
University Hospital.
Pilsen, Czechia
Synexus Czech
Prague, Czechia
Clinic
Prague, Czechia
Fakultni nemocnice v Motole
Prague, Czechia
MEDICAL PLUS s.r.o.
Uherské Hradiště, Czechia
Sydvestjysk Sygehus Esbjerg
Esbjerg, Denmark
JSC Saules seimos medicinos ce
Kaunas, Lithuania
Hospital of Lithuanian University of Health Sciences Kauno klinikos
Kaunas, Lithuania
Kaunas City Polyclinic
Kaunas, Lithuania
Lithuanian University of Health Sciences Hospital
Kaunas, Lithuania
Republican Siauliai Hospital
Šiauliai, Lithuania
Vilnius University Hospital Santaros Klinikos
Vilnius, Lithuania
National Osteoporosis Center
Vilnius, Lithuania
Osteo-Medic S.C. A Racewicz
Bialystok, Poland
Szpital Uniwersytecki
Bydgoszcz, Poland
Centrum Medyczne Pratia Czestochowa
Częstochowa, Poland
Synexus Polska
Częstochowa, Poland
Synexus Polska
Gdansk, Poland
Centrum Medyczne Pratia Gdynia
Gdynia, Poland
Synexus Polska
Gdynia, Poland
Silmedic sp. z o.o.,ul. Gen. Wladyslawa Sikorskiego
Katowice, Poland
Synexus Polska
Katowice, Poland
ETG Kielce, ul. Zagorska
Kielce, Poland
Krakowskie Centrum Medyczne
Krakow, Poland
ETG Lodz, ul. Pilota Stanislawa Wigury
Lodz, Poland
Synexus Polska
Lodz, Poland
ETG Lublin, ul. Kunickiego
Lublin, Poland
Twoja Przychodnia Nowosolskie Centrum Medyczne,
Nowa Sól, Poland
Prywatna Praktyka Lekarska
Poznan, Poland
Synexus Polska
Poznan, Poland
Twoja Przychodnia PCM
Poznan, Poland
ETG Siedlce
Siedlce, Poland
Twoja Przychodnia - Szczecinskie Centrum Medyczne
Szczecin, Poland
Showing 40 of 48 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.